Arch Biopartners (ARCH) Stock Statistics & Valuation Metrics

Arch Biopartners has a market cap or net worth of C$85.94M. The enterprise value is C$121.49M.

Arch Biopartners has 66,106,370 shares outstanding. The number of shares has decreased by -2.65% in one year.

Arch Biopartners’s return on equity (ROE) is 0.90 and return on invested capital (ROIC) is 250.18%.

The current PE Ratio of Arch Biopartners is ―. Arch Biopartners’s PEG ratio is -1.79.

In the last 12 months, Arch Biopartners had revenue of 2.12M and earned -3.92M in profits. Earnings per share was -0.06.

In the last 12 months, operating cash flow was -1.80M and capital expenditures 4.00, giving a free cash flow of -1.80M billion.

Arch Biopartners pays an annual dividend of ―, resulting in a dividend yield of ―

Arch Biopartners upcoming earnings date is Feb 3, 2026, TBA (Confirmed).

Arch Biopartners as a current ratio of 0.18, with Debt / Equity ratio of -66.67%

In the past 12 months, Arch Biopartners has paid 0.00 in taxes.

Arch Biopartners EV to EBITDA ratio is -32.56, with an EV/FCF ratio of -49.31.

Arch Biopartners has C$167.46K in cash and marketable securities with C$2.44M in debt, giving a net cash position of -C$2.27M billion.

Gross margin is 0.00%, with operating margin of -186.00%, and net profit margin of -184.73%.

The average price target for Arch Biopartners is ―, which is 11.43% higher than the current price. The consensus rating is ―